Division of Cardiovascular Medicine, Saint Louis University, Saint Louis, Missouri, USA.
Department of Medicine, Saint Louis University, Saint Louis, Missouri, USA.
Pacing Clin Electrophysiol. 2023 Sep;46(9):1099-1108. doi: 10.1111/pace.14784. Epub 2023 Jul 10.
New and persistent left bundle branch block (NP-LBBB) following Transcatheter Aortic Valve Replacement (TAVR) is an ongoing concern with incidence ranging from as low as 4% to up to 65% (varying for different types of valves). Such patients are at risk of developing high-grade atrioventricular block (HAVB) warranting permanent pacemaker (PPM) implantation. However, currently, there are no consensus guidelines or large prospective studies to risk stratify these patients for safer discharge after TAVR.
To provide insight from a single center study on using modified electrophysiology (EP) study to risk stratify post-TAVR patients to outpatient monitoring for low-risk versus pacemaker implantation for high-risk patients.
Between June 2020 and March 2023, all patients who underwent a TAVR procedure (324 patients) at our institution were screened for development of NP-LBBB post-operatively. Out of 26 patients who developed NP-LBBB, after a pre-specified period of observation, 18 patients were deemed eligible for a modified EP study to assess His-Ventricular (HV) interval. 11 out of 18 patients (61.1%) had normal HV interval (HV < 55 ms). Three out of 18 patients (16.7%) had HV prolongation (55 ms < HV < 70 ms) without significant HV prolongation (defined as an increase in HV interval > 30%) with intra-procedural procainamide challenge. Four out of 18 patients (22.2%) had significant HV prolongation (HV > 70 ms) warranting PPM implantation based on a multidisciplinary approach and shared decision-making with the patients. Total of 50% of patients discharged with PPM (two out of four patients) were noted to be pacemaker dependent based on serial device interrogations. All patients who did not receive PPM were discharged with ambulatory monitoring with 30-day event monitor and did not develop HAVB on serial follow-up.
Normal HV interval up to 55 ms on modified EP study after TAVR and development of NP-LBBB can be utilized as a threshold for risk stratification to facilitate safe discharge. The optimal upper limit of HV interval threshold remains unclear in determining appropriate candidacy for PPM.
经导管主动脉瓣置换术(TAVR)后新发持续性左束支传导阻滞(NP-LBBB)的发生率为 4%至 65%(不同类型瓣膜发生率不同),一直是一个令人关注的问题。此类患者有发生高度房室传导阻滞(HAVB)的风险,需要植入永久性起搏器(PPM)。然而,目前尚无共识指南或大型前瞻性研究对这些患者进行风险分层,以便在 TAVR 后更安全地出院。
提供单中心研究的见解,即使用改良电生理(EP)研究对 TAVR 后患者进行风险分层,以便对低风险患者进行门诊监测,对高风险患者进行起搏器植入。
2020 年 6 月至 2023 年 3 月,对我院接受 TAVR 手术的所有患者(共 324 例)进行筛查,以确定术后是否发生 NP-LBBB。在 26 例发生 NP-LBBB 的患者中,经过预先规定的观察期后,有 18 例患者符合进行改良 EP 研究的条件,以评估 His-Ventricular(HV)间期。18 例患者中有 11 例(61.1%)HV 间期正常(HV<55ms)。18 例患者中有 3 例(16.7%)HV 延长(55ms<HV<70ms),但无明显 HV 延长(定义为 HV 间期增加>30%),且术中用普鲁卡因胺进行了挑战。18 例患者中有 4 例(22.2%)HV 明显延长(HV>70ms),根据多学科方法和与患者的共同决策,需要植入 PPM。基于此,共有 50%的患者(4 例中的 2 例)出院时携带 PPM,根据连续设备检测结果,这些患者需要依赖起搏器。所有未植入 PPM 的患者出院时均携带动态监测仪进行门诊监测,在连续随访中未发生 HAVB。
TAVR 后改良 EP 研究中 HV 间期正常(55ms)和 NP-LBBB 可作为风险分层的阈值,以促进安全出院。确定适当的 PPM 候选者时,HV 间期的最佳上限阈值尚不清楚。